EMA/579335/2022

European Medicines Agency decision

P/0248/2022

of 8 July 2022

on the acceptance of a modification of an agreed paediatric investigation plan for dexmedetomidine (hydrochloride) (EMEA-002758-PIP01-19-M02) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0248/2022

of 8 July 2022

on the acceptance of a modification of an agreed paediatric investigation plan for dexmedetomidine (hydrochloride) (EMEA-002758-PIP01-19-M02) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/0019/2021 issued on 29 January 2021 and the decision P/0002/2022 issued on 7 January 2022,

Having regard to the application submitted by BioXcel Therapeutics, Inc. on 18 February 2022 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 20 May 2022, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan.

[1] OJ L 378, 27.12.2006, p.1, as amended.
[2] OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for dexmedetomidine (hydrochloride), oromucosal film, sublingual use, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to BioXcel Therapeutics, Inc., 555 Long Wharf Drive, 12th Floor, 06511 - New Haven, United States.

EMA/PDCO/135555/2022
Amsterdam, 20 May 2022

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMEA-002758-PIP01-19-M02

Scope of the application

Active substance(s):

Dexmedetomidine (hydrochloride)

Condition(s):

Treatment of schizophrenia

Treatment of bipolar disorder

Pharmaceutical form(s):

Oromucosal film

Route(s) of administration:

Sublingual use

Name/corporate name of the PIP applicant:

BioXcel Therapeutics, Inc.

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, BioXcel Therapeutics, Inc. submitted to the European Medicines Agency on 18 February 2022 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/0019/2021 issued on 29 January 2021 and the decision P/0002/2022 issued on 7 January 2022.

The application for modification proposed changes to the agreed paediatric investigation plan.

The procedure started on 21 March 2022.

Scope of the modification

Some measures of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion.

   The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of schizophrenia

The waiver applies to:

- the paediatric population from birth to less than 13 years of age;
- oromucosal film, sublingual use;
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s).

1.2. Condition:

Treatment of bipolar disorder

The waiver applies to:

- the paediatric population from birth to less than 10 years of age;
- oromucosal film, sublingual use;
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s).

2. Paediatric investigation plan

2.1. Condition:

Treatment of schizophrenia

2.1.1. Indication(s) targeted by the PIP

Rapid control of agitation in patients with schizophrenia

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 13 years to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Oromucosal film

2.1.4. Measures

Area	Description
Quality-related studies	***Study 1*** *deleted during EMEA-002758-PIP01-19-M02*
Non-clinical studies	Not applicable

Clinical studies	**Study 2 (BXCL501-PEDIATRIC)** Randomised, double-blind, placebo-controlled study evaluating the efficacy, safety and tolerability of dexmedetomidine in adolescents from 13 to less than 18 years of age with acute agitation associated with schizophrenia, and in children and adolescents from 10 to less than 18 years of age with acute agitation associated with bipolar disorder.
Extrapolation, modelling and simulation studies	**Study 3** Population pharmacokinetic and pharmacodynamic (PK/PD) analysis of sublingually administered dexmedetomidine in adults to determine paediatric dosing.
Other studies	Not applicable
Other measures	Not applicable

2.2. Condition:

Treatment of bipolar disorder

2.2.1. Indication(s) targeted by the PIP

Rapid control of agitation in patients with bipolar disorder

2.2.2. Subset(s) of the paediatric population concerned by the paediatric development

From 10 years to less than 18 years of age

2.2.3. Pharmaceutical form(s)

Oromucosal film

2.2.4. Measures

Area	**Description**
Quality-related studies	**Study 1** *Same as study 1 for condition treatment of schizophrenia*, *deleted during EMEA-002758-PIP01-19-M02.*
Non-clinical studies	Not applicable
Clinical studies	**Study 2 (BXCL501-PEDIATRIC)** *Same as study 2 for condition: Treatment of schizophrenia.*
Extrapolation, modelling and simulation studies	**Study 3** *Same as study 3 for condition: Treatment of schizophrenia.*
Other studies	Not applicable

Other measures	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By August 2024
Deferral for one or more measures contained in the paediatric investigation plan:	Yes